Prevalence of Synovitis in Patients With Haemophilia A

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorUniversity Hospital, Bonn

About this trial

The aim of this study is to evaluate the prevalence of synovitis in adult patients with haemophilia A.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Participants (≥ 18 years old) suffering from moderate or severe haemophilia A, also with inhibitor or joint replacement

Complete documentation of hemophilia severity, treatment history (past 12 months), and bleeding events (past 12 months), inhibitor status (at time of enrollment and in past medical history)

Submitted written consent to participate in the study

Disqualifiers

Patients suffering from other bleeding disorders conflicting with the research question

Patients in clinical studies with investigational drugs

Trial population

Adult patients (≥ 18 years of age) suffering from moderate (FVIII 1-5 %) or severe (FVIII \<1 %) haemophilia A.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US); Haemophilia joint health score (HJHS)

    Diagnostic test

    Each subject is examined for the presence of synovitis using the aforementioned diagnostics.

Treatment groups

300 Participants
are divided into 1 treatment group
Group A: Patients with Haemophilia A1 intervention

Trial outcomes

Primary outcomes

1

Haemophilia early arthropathy detection with ultrasound (HEAD-US)

HEAD-US protocol examines both elbow, knee and ankle joints sonographically and assesses the presence of synovitis or joint damage from 0-8 points per joint according to Martinoli et al. 2013. A "total score" of 0 to 48 points is achievable. A higher score means a worse joint status.

Time frame
20 minutes

Secondary outcomes

1

The Hemophilia Joint Health Score version 2.1 (HJHS)

Clinical joint examination according to De la Corte-Rodriguez et al. 2020. HJHS protocol examines both elbow, knee and ankle joints using a goniometer for range of motion and axial alignment (0-3 points), pain numerical rating scale (0-10 points), swelling (0-3 points), crepitation (0-2 points) and gait abnormalities (0-4 points). A "total score" of 0 to 124 points is achievable. A higher score means a worse joint status.

Time frame
45 minutes
2

PROMIS-29 Questionaire

Patient-reported outcomes are surveyed using short questionnaires with a stable number of items from seven PROMIS sub scales ("depression", "anxiety", "physical functioning", "impairment due to pain", "fatigue", "sleep impairment", "participation in social roles" and "activities"). The measures use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. For the sub scales "participation in social roles and activities" and "physical functioning", a high score is interpreted as a good result and for the sub scales "anxiety", "depression", "fatigue", "impairment due to pain", and "sleep impairment" a low score is a good result.

Time frame
10 minutes
3

Haemophilia Activities List (HAL)

to evaluate to subjective physical performance. A higher scores represent a better functional status. Scores can be calculated for each of ten domains of the HAL and a sum score ("Lying / sitting / kneeling / standing" (8-48 Points), "Functions of the legs" (9-54 Points), "Functions of the arms" (4-24 Points), "Use of transportation" (3-18 Points), "Self care" (5-30 Points), "Household tasks" (6-36 Points), "Leisure activities and sports" (7-42 Points), "Upper Extremity Activities" (9-54 Points), "Basic Lower Extremity Activities" (6-36 Points), "Complex Lower Extremity Activities" (9-54 Points), and "Sum score" (42-252 Points).

Time frame
10 minutes

Other outcomes

1

Baseline Characteristics

1. General anamnesis questionnaire (diseases, pain medication, surgeries, haemophilia related clinical data, date of birth, weight in kilograms, hight in centimeters. 2. Haemophilia treatment past twelve months (on demand/prophylaxis/non-factor therapy/EHL or SHL therapy) 3. Bleeding events past twelve months (traumatic or spontaneous)

Time frame
15 minutes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Bonn

Lead sponsor

Swedish Orphan Biovitrum

Collaborator